Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 13/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6294481 | 0.88 | CRHR1 (0.53) | CRHR1 | |
| SCHEMBL6294483 | 0.86 | CRHR1 (0.38) | CRHR1 | |
| SCHEMBL6290379 | 0.80 | CRHR1 (0.35) | CRHR1 | |
| SCHEMBL6295028 | 0.78 | CRHR1 (0.57) | CRHR1 | |
| SCHEMBL5600317 | 0.77 | CRHR1 (0.44) | CRHR1 | |
| SCHEMBL5599818 | 0.74 | CRHR1 (0.50) | CRHR1 | |
| SCHEMBL5707846 | 0.73 | CRHR1 (0.40) | CRHR1 | |
| SCHEMBL7445210 | 0.71 | CRHR1 (0.34) | CRHR1 | |
| SCHEMBL7615962 | 0.70 | CRHR1 (0.32) | CRHR1 | |
| SCHEMBL6290354 | 0.70 | CRHR1 (0.52) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1380298-A2 | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders, anorexia, inflammation | Bristol-Myers Squibb Pharma Company (US) | 2004-01-14 | — | — | EP | claimed |
| EP-0901374-B1 | TETRAHYDROPTERIDINES AND PYRIDYLPIPERAZINES FOR TREATMENT OF NEUROLOGICAL DISORDERS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-12-10 | — | — | EP | claimed |
| US-20030064993-A1 | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders | WILDE RICHARD GERALD (US) | 2003-04-03 | — | — | US | claimed |
| US-6399609-B1 | CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-04 | — | — | US | claimed |
| EP-0901374-A4 | TETRAHYDROPTERIDINES AND PYRIDYLPIPERAZINES FOR TREATMENT OF NEUROLOGICAL DISORDERS | DU PONT PHARM CO (US) | 2001-05-09 | — | — | EP | claimed |
| EP-0901374-A1 | TETRAHYDROPTERIDINES AND PYRIDYLPIPERAZINES FOR TREATMENT OF NEUROLOGICAL DISORDERS | Du Pont Pharmaceuticals Company (US) | 1999-03-17 | — | — | EP | claimed |
| WO-1997044038-A1 | TETRAHYDROPTERIDINES AND PYRIDYLPIPERAZINES FOR TREATMENT OF NEUROLOGICAL DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 1997-11-27 | — | — | WO | claimed |
| US-6869955-B2 | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
| EP-1380298-A2 | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders, anorexia, inflammation | Bristol-Myers Squibb Pharma Company (US) | 2004-01-14 | — | — | EP | disclosed |
| EP-0901374-B1 | TETRAHYDROPTERIDINES AND PYRIDYLPIPERAZINES FOR TREATMENT OF NEUROLOGICAL DISORDERS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20030064993-A1 | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders | WILDE RICHARD GERALD (US) | 2003-04-03 | — | — | US | disclosed |
| US-6399609-B1 | CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-04 | — | — | US | disclosed |
| US-6083948-A | TREATING ANXIETY, DEPRESSION, AND OTHER PSYCHIATRIC AND NEUROLOGICAL DISORDERS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064993-A1 | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders | CRH, CRHR1, CRHR2 | CRHR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.